Can Targeting Immunosuppressive Molecules Enhance Cancer Treatment?
Yes, targeting immunosuppressive molecules is a promising strategy to enhance cancer treatment. For example, combining checkpoint inhibitors with agents that target other immunosuppressive pathways, such as TGF-β or IDO inhibitors, can potentially improve therapeutic outcomes. This combinatorial approach aims to create a more favorable immune environment for the activation and persistence of anti-tumor immune responses.
